Precision Medicine for Chronic Wounds


Chronic wounds are a high unmet medical need worldwide

Definition: chronic wounds are wounds that fail to heal within a period of up to 8 weeks
Typical examples: venous and/or arterial leg ulcers, diabetic foot ulcers, or pressure ulcers (decubitus)
Burden for the patient: chronic wounds cause morbidity and increased mortality
Treatment options: unsatisfactory, no new drugs in > 15 years
Patient population: 10-20 million chronic wound patients in Europe and US
Treatment costs: 2 – 5% of total health care costs, i.e., > 100 billion USD/year in EU and US


All chronic wounds are different

Chronic wounds have a multifactorial etiology and are dependent on many different variables.

There is no test system for the prediction of treatment success.


Innovation of chronic wound therapy through a novel assay platform and drugs

From bedside to bench and back to bedside


Akribes Biomedical GmbH, founded in 2015, is a privately owned limited liability company located in Vienna, Austria.

Our Mission

We want to make chronic wounds heal.

Our Vision

We want to offer personalized therapy by matching patients and their best treatment options.

Akribes has developed proprietary assay systems, using wound exudates from patients.

By use of these assay systems, Akribes has identified and patented compounds and compound classes with so far unknown potential for the treatment of chronic wounds.

Akribes team


Dr. Barbara Wolff-Winiski, MBA

Co-Founder, CEO & CSO

30 years of experience in academia and drug R&D (Novartis). Senior scientist and project team head for various preclinical dermatology projects.

Dr. Barbara Wolff-Winiski, MBA worked at Novartis for 25 years. She established diverse in vitroin vivo and ex vivo assays to profile lead compounds for inflammatory skin diseases and skin cancer. In 2012 she received the Novartis 3R Animal Welfare Award for the development of an in vitro organotypic 3D keratinocyte model of Netherton disease. As Project Team Head and lead scientist, she provided pivotal preclinical data to advance new medical entities to clinical development, e.g., inhibitors of protein kinase C, smoothened and proteases.

Read More

Prof. Dr. Anton Stütz

Co-Founder, CEO

40 years of experience in drug R&D and management (Novartis). Inventor of Lamisil®, leading scientist for Elidel®. Recipient of national and international awards.

Prof. Dr. Anton Stütz, former Executive Director Dermatology, spent 39 years in drug discovery and development with Novartis (former Sandoz), with managerial responsibilities for up to 100 employees.

He is the inventor of the antifungal block buster drug terbinafine (Lamisil®), the dermatological use of calcineurin inhibitors, e.g. tacrolimus (Protopic®), and the leading scientist for R&D of pimecrolimus (Elidel®).

He received the Erwin Schroedinger Preis by Austria´s Academy of Sciences in 2004, the Eugene J. Van Scott Award for Innovative Therapy of the Skin, and the Philipp Frost Leadership Lecture by the American Academy of Dermatology in 2011.

Read More

Mag. Lukas Kadawy


Lukas served as Chief Financial Officer at Apeiron Biologics AG from 2005 to 2015. He has since co-founded other biotech and diagnostic companies and started his own consultancy business to support scientific founders.

In his corporate roles, he helped manage the growth of companies from start-up to grown-up stages with 30+ employees, with projects ranging from early-stage research projects, across mid- to late-stage clinical programs all the way through to marketing authorization (Qarziba® for the treatment of neuroblastoma).

He handled various equity and debt-based financing rounds, in- and out-licensing agreements with Big Pharma, spin-outs, and his responsibilities included legal affairs, business development, administration, HR and investor relations.

Read More


Dr. Petra Dörfler


Experience in academia, pharmaceutical and biotech industry. Senior scientist and project team head for diverse projects in immunology.

Nicole Schöfmann, BSc


Extensive technical experience in immunology and dermatology in the pharmaceutical industry. Additional degree in Occupational Therapy.

Gabriela Cabral, PhD


Experience in academic research. Strong publication record in cell biology. Additional training in Project Management.

Maria Rita Casari, PhD


Experience in academic research (molecular and cell biology). Background in Pharmacy.

Advisory board

Professor Dr. Gustav Ammerer

Department of Biochemistry and Cell Biology
University of Vienna
Vienna, Austria

Professor Dr. Thomas Luger

Department of Dermatology
University of Münster
Münster, Germany

Dr. Friedrich K. Mayer

Oberwil, Switzerland

Professor Dr. Kim Nasmyth

Department of Biochemistry
University of Oxford
Oxford, UK

Professor Dr. Georg Stingl

Division of Immunology, Allergy and Infectious Diseases Department of Dermatology
Medical University of Vienna
Vienna, Austria

Professor Dr. Sabine Werner

Department of Biology
Institute of Molecular Health Sciences
Swiss Federal Institute of Technology (ETH)
Zürich, Switzerland

Collaboration Partners

Akribes is part of the Horizon Europe project Force Repair
Akribes Biomedical is an affiliated company of SKINTEGRITY.CH


Project funded by the European Union
Copyright © 2022 - Akribes Biomedical GmbH